About ORIGAMI THERAPEUTICS, INC.
Origami Therapeutics is a preclinical-stage biopharmaceutical company focused on developing novel protein degrader therapeutics for neurodegenerative diseases such as Huntington’s Disease. The company utilizes a proprietary drug discovery platform to target and degrade disease-causing proteins.
Developing next-generation disease-modifying protein degraders and correctorsProprietary ORICISION™ Drug Discovery PlatformTargeting and degrading disease-related proteins using the body’s natural protein disposal systemFocusing on neurodegenerative diseases including Alzheimer’s, Huntington’s, Parkinson’s, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ORIGAMI THERAPEUTICS, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.